Direct answer: Interpersonal therapy (IPT) is a structured depression treatment focused on relationships and life circumstances linked with mood. It is not simply relationship advice, and it does not assume another person caused the illness. A trained provider helps select a relevant focus and assess symptoms and functioning. Confidence is high in the need for appropriate assessment and safety review, and moderate in this selected summary of clinical care pathways. A supplement substitute is not independently established here. Recommendations are not relabeled as clean, independently replicated trial results (NIMH depression).
Key takeaways
- Interpersonal therapy (IPT) is a structured depression treatment focused on relationships and life circumstances linked with mood.
- The desired outcome includes reduced depressive symptoms and improved functioning, with relationship changes that matter to the person.
- Suicidal intent, psychotic symptoms or inability to manage basic needs requires urgent assessment.
Table of contents
- Evidence summary
- What it is
- How it works
- The evidence-based treatments
- Supplement and lifestyle evidence
- What works and what does not
- Risks and side effects
- Important interactions
- Who should avoid unsupervised treatment
- Dosage and how to take
- Animal and in-vitro evidence
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
The source roles below are deliberately different. A health-agency explanation can support definitions and a clinical guideline can describe recommended care; neither automatically clears the funding of its supporting trials. This selected review does not provide a newly pooled treatment-effect estimate.
| Question | Source | Funding / conflict | Interpretation and limits |
|---|---|---|---|
| What needs assessment? | NIMH depression | Public institutional education; complete individual disclosures may be unavailable. | Clinical background; no online self-diagnosis. |
| Which care options are discussed? | NICE adult depression guidance; NIMH psychotherapies | Institutional funding checked; every supporting trial has not been screened. | Recommendation/context role; no sponsor-independent effect size claimed. |
| What are medicine and safety limits? | NIMH mental health medications; NIMH suicide warning signs | US publicly funded education. | General precautions; individual decisions require clinical review. |
| Can supplements replace care? | NCCIH depression | Public summary; included-study finances vary. | No independently verified replacement regimen established in this review. |
What it is
Depression and interpersonal problems can influence each other. Loss, changing roles or relationship difficulties may be relevant to a clinical formulation. NIMH describes IPT as helping with communication, support and realistic expectations around interpersonal events. NICE includes it among structured depression treatments. The work is tailored to current needs rather than requiring every patient to identify one guilty person or recount every past relationship. A practical target might concern a transition or a conflict, but this article does not assign one to an individual reader. (NIMH depression).
How it works
The treatment model examines how interpersonal circumstances affect mood and how depression affects interactions. That reciprocal relationship is different from proving a single cause. Relationships can be supportive, stressful or unsafe. A person experiencing abuse needs safeguarding and practical help; communication exercises should not assume equal power or remove responsibility from the abuser. The presence of a relationship problem also does not rule out bipolar depression, medical illness or another contributor requiring assessment. (NIMH depression).
The evidence-based treatments
NICE describes IPT delivered by a practitioner with therapy-specific competence and a structured focus. Selection depends on the depressive presentation, preferences, prior care and circumstances. It may be considered alone or alongside medicine within an assessed treatment plan. A generic counselling or couples course should not be assumed identical to IPT. NIMH recommends asking about the rationale, goals, provider expertise and how progress will be evaluated. This selected source set reports clinical-care options without independently clearing every supporting trial or assigning a comparative numerical effect. Ask how the proposed focus relates to the depression and how the provider will reassess care if mood or functioning does not improve. (NIMH depression; NICE adult depression guidance).
Supplement and lifestyle evidence
No supplement is established here as a replacement for this care pathway. Evidence about general relaxation or a change in a biomarker does not demonstrate the clinical outcome under discussion. Original product trials would need separate review of financing, material gifts, authors and harms before an independent conclusion could be made. Daily routines and practical support can make participation easier, but their role should remain specific rather than becoming a promise of recovery (NCCIH depression).
What works and what does not
The desired outcome includes reduced depressive symptoms and improved functioning, with relationship changes that matter to the person. Feeling understood during a conversation can be valuable but does not prove that a complete depressive episode has resolved. Therapy attendance, communication satisfaction and clinical recovery are distinct measures.
Risks and side effects
Suicidal intent, psychotic symptoms or inability to manage basic needs requires urgent assessment. When violence or abuse is present, explain it to the provider so safety can be addressed; joint work should not be improvised as a substitute for protection.
Thoughts of suicide, a plan to act, or inability to keep yourself or another person safe need urgent help. In an immediate danger, contact local emergency services; in the United States, 988 provides crisis support and 911 is for life-threatening emergencies. These numbers are jurisdiction-specific. Tell a trusted person and obtain help rather than relying on an article or supplement. If someone is at immediate risk, do not leave them alone while arranging safe assistance (NIMH suicide warning signs).
Medicines can cause unwanted effects and some require monitoring or a gradual stopping plan. New agitation, marked behavioural change or worsening suicidal thoughts should be reported promptly, particularly around starting or changing an antidepressant. A difficult therapy session should be discussed too; agreed pacing and safety matter (NIMH mental health medications).
Important interactions
Share relevant prescribed treatment and substance use with the provider. IPT does not authorize changing medicines or treating physical symptoms as relationship problems. Coordination helps keep the therapeutic focus and medical care aligned. (NIMH mental health medications; NIMH psychotherapies).
Who should avoid unsupervised treatment
Avoid substituting generic relationship coaching for assessment when depression is severe or safety is uncertain. Abuse, major cognitive or communication needs and complex illness may require adapted or specialist care. (NICE adult depression guidance).
Dosage and how to take
No universal session count or personal communication regimen is prescribed. Agree the focus, goals, duration and review points with the trained provider, including a route to discuss deterioration between appointments. (NICE adult depression guidance).
Animal and in-vitro evidence
Changes in stress hormones, neurotransmitters or behaviour in cells or animals are clues to mechanisms. They cannot establish clinical recovery, functional improvement or safety in a person with this clinical or occupational problem. Nor does laboratory activity identify the right human product, formulation or dose. This article excludes animal and cell findings from human efficacy conclusions. Mechanistic plausibility is kept separate from the clinical guidance summarized above.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 3 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Tier describes financial independence; the letter grade describes credibility for the stated use, not treatment potency. The source mix is concentrated in US and UK institutions, with international sources where indicated. Public funding is checked but does not erase individual or trial-level ties. Medicine, device, therapy, app and supplement providers may earn revenue from care; clinicians and institutions also have professional and service incentives. Those interests do not establish misconduct or a payment to this article.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NIMH depression | US NIH/HHS federal appropriations; NIMH budget route. NIMH also accepts donations and bequests through its separate Gift Fund, which can support public information. Page-specific donor allocation and individual contributor finances were not established. | United States; Bethesda, Maryland; federal health research agency. | Tier 1 public appropriations plus disclosed donation route; page-level independence provisional and underlying trial finances vary. | B, provisional: public accountability and scientific reputation reward accuracy. Education is simplified; the institution also promotes its research mission. No blanket trial clearance. |
| NICE adult depression guidance | NICE: Department of Health and Social Care grants plus NHS, fee and other income; 2025–26 accounts. Complete guideline-committee and underlying-trial commercial provenance not cleared here. | United Kingdom; England; public guideline institution. | Tier 2 institutional indirect fee interests; individual/trial status provisional. | B, provisional for guideline interpretation; material source-specific author ties, when unverified, remain a gap. Clinical accuracy and public accountability coexist with cost/service priorities. No independent efficacy verdict inferred. |
| NIMH psychotherapies | US NIH/HHS federal appropriations; NIMH budget route. NIMH also accepts donations and bequests through its separate Gift Fund, which can support public information. Page-specific donor allocation and individual contributor finances were not established. | United States; Bethesda, Maryland; federal health research agency. | Tier 1 public appropriations plus disclosed donation route; page-level independence provisional and underlying trial finances vary. | B, provisional: public accountability and scientific reputation reward accuracy. Education is simplified; the institution also promotes its research mission. No blanket trial clearance. |
| NIMH mental health medications | US NIH/HHS federal appropriations; NIMH budget route. NIMH also accepts donations and bequests through its separate Gift Fund, which can support public information. Page-specific donor allocation and individual contributor finances were not established. | United States; Bethesda, Maryland; federal health research agency. | Tier 1 public appropriations plus disclosed donation route; page-level independence provisional and underlying trial finances vary. | B, provisional: public accountability and scientific reputation reward accuracy. Education is simplified; the institution also promotes its research mission. No blanket trial clearance. |
| NIMH suicide warning signs | US NIH/HHS federal appropriations; NIMH budget route. NIMH also accepts donations and bequests through its separate Gift Fund, which can support public information. Page-specific donor allocation and individual contributor finances were not established. | United States; Bethesda, Maryland; federal health research agency. | Tier 1 public appropriations plus disclosed donation route; page-level independence provisional and underlying trial finances vary. | B, provisional: public accountability and scientific reputation reward accuracy. Education is simplified; the institution also promotes its research mission. No blanket trial clearance. |
| NCCIH depression | US NIH/HHS public appropriations; funding-process documentation. This dated request is not a verified current allocation. NIH gift authority permits conditional and unconditional gifts; actual NCCIH page-specific donor support was not established. | United States; Bethesda, Maryland; federal institution. | Tier 1 institution, provisional; supporting study funding not cleared. | B, provisional: public safety remit and research accountability. Complementary-health research mission and selective summaries remain relevant. Used for limits and safety, not a clean product-effect estimate. |
Frequently asked questions
Is IPT couples counselling?
They are different approaches, although both can involve interpersonal issues. Ask which treatment is being offered and why.
Must relationships be the only cause?
No. Depression has multiple contributors and a treatment focus is not proof of a sole cause.
Can medicine be used too?
It may be appropriate in an individualized plan, with the prescriber coordinating medication decisions.
Sources and funding notes
Original source pages were opened for this review, including recommendation text where a guideline is cited. The institution-level funding routes were checked; page-level contributors, guideline declarations and the full financial chain of supporting studies are not all cleared. Public recommendations are therefore reported as guidance, and no drug, device or supplement is assigned an independently verified effect size. Source dates vary and some pages predate the review. This is an educational, selected review rather than an exhaustive systematic search or personal medical advice.
- NIMH depression — Revised 2024
- NICE adult depression guidance — Exact source review date not established
- NIMH psychotherapies — Last Reviewed: February 2024
- NIMH mental health medications — Last Reviewed: December 2023
- NIMH suicide warning signs — Revised 2023
- NCCIH depression — Last Updated: February 2020
Last reviewed: October 4, 2026.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.